医学
无容量
吉西他滨
顺铂
危险系数
尿路上皮癌
转移性尿路上皮癌
肿瘤科
泌尿科
内科学
无进展生存期
胃肠病学
免疫疗法
置信区间
化疗
外科
膀胱癌
癌症
作者
Michiel S. van der Heijden,Guru Sonpavde,Thomas Powles,Andrea Necchi,Mauricio Burotto,Michael Schenker,Juan Pablo Sade,Aristotelis Bamias,Philippe Beuzeboc,Jens Bedke,Jan Oldenburg,Gurkamal Chatta,Yüksel Ürün,Dingwei Ye,Zhisong He,Begoña P. Valderrama,Ja Hyeon Ku,Yoshihiko Tomita,Jeiry Filian,Lily Wang
标识
DOI:10.1056/nejmoa2309863
摘要
Combination therapy with nivolumab plus gemcitabine-cisplatin resulted in significantly better outcomes in patients with previously untreated advanced urothelial carcinoma than gemcitabine-cisplatin alone. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 901 ClinicalTrials.gov number, NCT03036098.).
科研通智能强力驱动
Strongly Powered by AbleSci AI